🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

123+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 123 recruiting trials for “Systemic lupus erythematosus

Phase 2RecruitingNCT07363460

Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN

👨‍⚕️ bicheng Liu, Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine📍 1 site📅 Started Nov 2025View details ↗
Phase 1RecruitingNCT07236801

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

🏥 China Immunotech (Beijing) Biotechnology Co., Ltd.📍 2 sites📅 Started Nov 2025View details ↗
RecruitingNCT06795893

The Anifrolumab PRIM Program

👨‍⚕️ Syd Philips, PPD Miami, US📍 1 site📅 Started Nov 2025View details ↗
Phase 1RecruitingNCT07361094

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

🏥 Beijing Boren Hospital📍 1 site📅 Started Nov 2025View details ↗
EARLY_Phase 1RecruitingNCT07339540

the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases

🏥 Tongji Hospital📍 1 site📅 Started Nov 2025View details ↗
Phase 1RecruitingNCT07233642

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

👨‍⚕️ Jianhua Mao, MD, Children's Hospital of Zhejiang University School of Medicine📍 1 site📅 Started Nov 2025View details ↗
Phase 1, PHASE2Enrolling by InvitationNCT07221565

Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting

👨‍⚕️ Gavin Solomon, President & CEO, Truway Health, Inc.📍 1 site📅 Started Oct 2025View details ↗
RecruitingNCT07352332

Immune Profiling of Refractory cSLE Exposed to CD3×CD19 BiTE

🏥 The Children's Hospital of Zhejiang University School of Medicine📍 1 site📅 Started Sep 2025View details ↗
EARLY_Phase 1RecruitingNCT07193810

A Study of CC312 for Relapsed/Refractory Autoimmune Diseases

🏥 CytoCares Inc📍 1 site📅 Started Sep 2025View details ↗
Phase 1, PHASE2RecruitingNCT07185269

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

🏥 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.📍 1 site📅 Started Sep 2025View details ↗
Phase 1RecruitingNCT07177911

Safety and Efficacy Study of CC312 for Moderate to Severe SLE

🏥 CytoCares Inc📍 1 site📅 Started Sep 2025View details ↗
Phase 1RecruitingNCT07237659

Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA

👨‍⚕️ Andreas Reiff, PhD, MD, Neutrolis📍 1 site📅 Started Sep 2025View details ↗
EARLY_Phase 1RecruitingNCT07174843

An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases

🏥 Shanghai Cell Therapy Group Co.,Ltd📍 1 site📅 Started Sep 2025View details ↗
Phase 1, PHASE2RecruitingNCT07010835

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

🏥 Excyte Biopharma Ltd📍 1 site📅 Started Aug 2025View details ↗
Phase 4RecruitingNCT07077486

Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease

🏥 Tongji Hospital📍 1 site📅 Started Aug 2025View details ↗
Phase 1RecruitingNCT07123519

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

🏥 China Immunotech (Beijing) Biotechnology Co., Ltd.📍 1 site📅 Started Aug 2025View details ↗
Phase 1RecruitingNCT07104721

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

🏥 China Immunotech (Beijing) Biotechnology Co., Ltd.📍 1 site📅 Started Aug 2025View details ↗
EARLY_Phase 1RecruitingNCT07072611

Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

🏥 Noxopharm Limited📍 1 site📅 Started Jul 2025View details ↗
Phase 1RecruitingNCT07031713

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

🏥 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology📍 1 site📅 Started Jul 2025View details ↗
Phase 1Enrolling by InvitationNCT07038447

A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

👨‍⚕️ Kite Study Director, Kite, A Gilead Company📍 5 sites📅 Started Jul 2025View details ↗
← PreviousPage 2 of 7Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →